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Abstract
It has become widely recognised that outpatient treatment may be suitable for many patients with venous
thromboembolism. In addition, non-vitamin K antagonist oral anticoagulants that have been approved over the last
few years have the potential to be an integral component of the outpatient care pathway, owing to their oral route
of administration, lack of requirement for routine anticoagulation monitoring and simple dosing regimens.
A robust pathway for outpatient care is also vital; one such pathway has been developed at Sheffield Teaching
Hospitals in the UK. This paper describes the pathway and the arguments in its favour as an example of best
practice and value offered to patients with venous thromboembolism.
The pathway has two branches (one for deep vein thrombosis and one for pulmonary embolism), each with the
same five-step process for outpatient treatment. Both begin from the point that the patient presents (in the
Emergency Department, Thrombosis Clinic or general practitioner’s office), followed by diagnosis, risk stratification,
treatment choice and, finally, follow-up.
The advantages of these pathways are that they offer clear, evidence-based guidance for the identification,
diagnosis and treatment of patients who can safely be treated in the outpatient setting, and provide a detailed,
stepwise process that can be easily adapted to suit the needs of other institutions. The approach is likely to result
in both healthcare and economic benefits, including increased patient satisfaction and shorter hospital stays.
Keywords: Deep vein thrombosis, Oral anticoagulant, Patient pathway, Pulmonary embolism, Venous
thromboembolism
Background
Historically, patients diagnosed with deep vein thrombosis
(DVT) and pulmonary embolism (PE) have been treated
as inpatients owing to the potential for serious complica-
tions, including death. In recent years it has been recog-
nised that many patients with acute DVT may be safely
treated in the outpatient setting. Furthermore, it is
possible to identify patients with acute PE who are at low
risk of deterioration and may also be suitable for ambula-
tory management or early discharge [1–4].
Appropriate outpatient management of DVT and PE
may be beneficial to patients and the healthcare system
alike. Potential benefits include improvements in patient
satisfaction and reduced healthcare costs associated with
a shorter hospital stay. Limited data are available to
compare these outcomes and further research is needed
[5]. Non-vitamin K antagonist (VKA) oral anticoagulant
(NOAC) therapy may provide benefits for patient
management in ambulatory care compared with low mo-
lecular weight heparin (LMWH) overlapping with, and
followed by, a VKA [6]. NOAC therapy involves oral ad-
ministration, no routine coagulation monitoring require-
ments, a single-drug approach (with rivaroxaban and
apixaban) and fewer follow-up appointments [6].
One potential disadvantage of ambulatory care is that
opportunities for follow-up, patient education and com-
munication between primary and secondary care may be
lost if a patient is discharged from hospital without an
adequate protocol in place. Healthcare professionals
(HCPs) at Sheffield Teaching Hospitals have developed a
patient pathway for venous thromboembolism (VTE)
management to improve the transition of patients from
hospital to home. This pathway has proved effective in
ensuring adequate follow-up and communication
between all HCPs involved. The development of such a
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pathway can also help streamline processes and clinical
decision-making, improving efficiency and ensuring con-
sistent high-quality care. This article presents the
Sheffield VTE management pathways for DVT and PE
as examples of best practice, demonstrating their value
in VTE management, and discusses the benefits of
NOAC use in ambulatory care.
Venous thromboembolism management
In the UK, the management of DVT varies widely. A re-
cent UK audit reported a lack of coordinated services in
this area and called for standardised and consistent pro-
tocols [7]. The Sheffield pathway is an evidence-based
pathway, developed by the whole VTE management
team, in which low-risk patients may be treated in an
ambulatory care setting, while patients at higher risk are
admitted to hospital. This approach also reduces the as-
sociated burden on healthcare resources and patients’
time. A treatment pathway also provides clarity in an
area with a large choice of diagnostic tools, an increasing
number of treatment options and various forms of pres-
entation (e.g. provoked or unprovoked, mild, moderate
or severe symptoms). In the past, many hospitals had an
uncoordinated VTE management strategy with a range
of diagnostic assessment, treatment, and patient follow-
up pathways, depending on which department the pa-
tient presented to [8, 9]. Optimal VTE management in-
cludes rapid assessment, diagnosis and treatment;
patient information and support; and follow-up. Follow-
up allows clinical improvement to be confirmed, chronic
complications to be monitored and an optimal anticoa-
gulation approach to be planned.
The Sheffield venous thromboembolism management
pathway: deep vein thrombosis
Typically, a patient may enter the Sheffield DVT pathway
in one of three ways. A patient may: 1) present directly to
the Emergency Department and be transferred to the
Thrombosis Clinic (open during working hours); 2) visit
their general practitioner and be referred to the Thrombosis
Clinic/Emergency Department; or 3) present as an inpatient
(e.g. in the instance of a post-operative venous thrombo-
embolic event). These three entry levels involve contact
with several hospital HCPs, including nurses, VTE specialist
nurses, junior doctors, pharmacists and consultants (col-
lectively, the multidisciplinary team [MDT]). The type of
VTE diagnosed and the patient’s medical history determine
which members of the MDTare involved in each individual
patient pathway, including longer-term follow-up.
Step 1: Patient presentation
When a patient presents with suspected DVT, a general
medical history and physical examination will be con-
ducted; if DVT is considered likely, the patient will enter
the DVT pathway (Fig. 1). If a specialist nurse in the
Thrombosis Clinic is not available, an Emergency
Department physician will assess the patient.
Step 2: Diagnosis in the thrombosis clinic (or by
emergency department physician)
The validated two-level DVT Wells’ score indicates
whether a DVT is likely or unlikely based on the pa-
tients clinical signs, symptoms and through exclusion of
other causes [10]. A score of ≥2 indicates that DVT is
likely; a score of ≤1 indicates that DVT is unlikely
(Table 1) [10]. The likelihood of DVT can be further de-
termined by a blood test for D-dimer, a degradation
product of a blood clot. D-dimer levels are typically ele-
vated in patients with an acute VTE [11]. However, a
negative D-dimer result is more clinically important in
order to ‘rule out’ DVT, because a positive result can
arise in conditions other than DVT [11].
If DVT is considered a likely diagnosis, the patient will
be sent for an ultrasound scan, preferably on the same
day. If the ultrasound scan is scheduled for the following
day or after a weekend, immediate anticoagulation with
a LMWH injection is administered.
Step 3: Risk stratification
At the point of diagnosis, and when considering DVT
treatment options, each patient must be assessed for com-
plications and frailty. This may determine the treatment
type, level of observation required and whether treatment
can be safely administered at home. Most DVT cases can
be managed safely at home, but for certain patients, for
example if the event is post-operative or if the patient is at
high risk of falling, a hospital stay may be required.
Certain patients with proximal iliofemoral DVT may be
candidates for catheter-directed thrombolysis. Risk of
bleeding events within the first 3–6 months of
Diagnosed in ED
or as an inpatient













Fig. 1 Sheffield deep vein thrombosis pathway. DVT, deep vein
thrombosis; ED, Emergency Department; MDT, multidisciplinary
team; OPA, outpatient appointment
Condliffe Thrombosis Journal  (2016) 14:47 Page 2 of 8
anticoagulation may be assessed using the HAS-BLED
(Hypertension, Abnormal renal and liver function, Stroke,
Bleeding, Labile international normalised ratios, Elderly,
Drugs or alcohol) [12] or the RIETE (based on recent
major bleeding, creatinine >1.2 mg/mL, anaemia, cancer,
clinically overt PE and age >75 years) risk scores [13]. The
HAS-BLED score was derived from patients receiving
anticoagulation for atrial fibrillation. The utility of these
studies in assessing early risk of bleeding is limited.
Step 4: Treatment strategy
In Sheffield, until recently, the majority of patients diag-
nosed with DVT were treated initially with LMWH
while warfarin therapy was commenced. Patients receiv-
ing warfarin require routine coagulation monitoring to
ensure that they stay within the therapeutic range, evalu-
ated with the international normalised ratio [14]. Several
other choices of anticoagulation are now available in
Europe, with the NOACs apixaban, dabigatran, edoxa-
ban and rivaroxaban approved for the treatment of acute
DVT and PE [15–18]. These therapies do not require
routine coagulation monitoring and have all been shown
to be non-inferior to warfarin in terms of VTE
recurrence [19–22].
To improve clinician familiarity and hence patient
safety, we have elected to use a single NOAC for the initial
treatment of VTE. In the Sheffield DVT pathway the
majority of DVT cases are managed using rivaroxaban if
patients have a creatinine clearance ≥30 mL/min, unless
contraindicated. This oral, single-drug approach – 15 mg
twice daily for the first 21 days and then 20 mg once daily
for longer-term treatment – is a simple regimen that facil-
itates the majority of patients being treated at home [15].
Other NOACs are considered after initial anticoagulation
on a case-by-case basis.
Step 5: Follow-up
An outpatient appointment with the thrombosis nurse at
the Thrombosis Clinic is arranged for all patients
undergoing outpatient management, approximately
21 days after the initial DVT event. This aligns with when
the rivaroxaban dose, if rivaroxaban is the prescribed drug,
is changed to 20 mg once daily. The patient is provided
with education about their anticoagulation therapy, in-
cluding the importance of adherence to treatment, warn-
ing signs for bleeding, symptoms of recurrent VTE and
when to contact a HCP. The patient is also provided with
a contact number for the Thrombosis Clinic if they need
to access more information.
For patients with an unprovoked DVT, in which the
cause of DVT is unclear, an outpatient appointment with
a consultant haematologist is arranged to discuss long-
term therapy. In patients for whom malignancy is sus-
pected, an outpatient appointment is booked within
2 weeks of initial presentation to discuss options for fur-
ther investigations or scans. Thrombophilia testing may
also be arranged in selected patients. The initial treat-
ment duration with rivaroxaban is 3 months, and
longer-term treatment is discussed when appropriate.
The Sheffield venous thromboembolism management
pathway: pulmonary embolism
Step 1: Patient presentation
Patients may present with symptoms indicative of an
acute PE either to their general practitioner (leading to
referral to the Emergency Department) or directly to the
Emergency Department, where they enter into the PE
pathway (Fig. 2).
Step 2: Diagnosis in the thrombosis clinic (or by emergency
department physician)
The two-level Wells’ PE score is used to determine
whether PE is a likely or unlikely diagnosis [23]. The
Wells’ PE score – both the full and simplified versions –
has been validated for use in clinical settings [24, 25].
The score includes clinical signs and symptoms of DVT,
PE as the most likely diagnosis, heart rate >100 bpm, re-
cent immobilisation or surgery, previous VTE, haemopty-
sis and active or previous malignancy (Table 2) [23]. If the
simplified Wells’ score suggests that PE is likely, the pa-
tient proceeds to diagnostic imaging, most commonly
computed tomography pulmonary angiogram, with venti-
lation/perfusion single-photon emission computed
Table 1 Deep vein thrombosis Wells’ score [10]
Criteria Points
Active cancer +1
Paralysis, paresis or recent plaster
cast of the lower limb
+1
Bedridden for 3+ days or major






Calf swelling >3 cm more than
asymptomatic leg
+1
Pitting oedema in symptomatic
leg only
+1
Collateral superficial veins +1
History of DVT +1
Alternative cause is considered
at least as likely as DVT
−2
Outcome:
DVT unlikely: Score ≤1 (consider
trauma, cellulitis)
DVT likely: Score ≥2
DVT deep vein thrombosis
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tomography being reserved for patients with significant
renal dysfunction, contrast allergy or pregnancy. If the
simplified Wells’ score suggests that PE is unlikely, D-
dimer levels are used to identify patients in whom diag-
nostic imaging is not required. Although withholding of
anticoagulation in patients with levels below an age-
adjusted D-dimer threshold (age in years × 10) was dem-
onstrated to be associated with a very low risk of subse-
quent VTE, these data have not been validated in other
populations [26]. Therefore, the current approach is to
use a standard threshold of <500 ng/mL to exclude acute
PE in patients with a simplified Wells’ score of ≤4 [1].
Step 3: Risk stratification
Following diagnosis of acute PE, patients undergo risk as-
sessment for early deterioration. Patients with low blood
pressure (<90/60 mmHg) and/or signs of clinical shock
(high-risk patients) should be considered for immediate
reperfusion therapy, most commonly with systemic
thrombolysis [1]. Non-high-risk patients may be further
categorised into intermediate- and low-risk groups based
on a combination of risk score and markers of right ven-
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NOAC*





















*Pre-treatment with LMWH not required for apixaban or rivaroxaban
Fig. 2 Sheffield pulmonary embolism pathway. CTEPH, chronic thromboembolic pulmonary hypertension; CTPA, computed tomography pulmonary
angiogram; LMWH, low molecular weight heparin; OAC, oral anticoagulant; PE, pulmonary embolism; VQ SPECT, ventilation/perfusion single-photon
emission tomography [35]





Clinical signs and symptoms of DVT
(minimum of leg swelling and pain
with palpation of the deep veins)
3 1
An alternative diagnosis is less
likely than PE
3 1
Heart rate ≥100 beats per minute 1.5 1
Immobilisation (for >3 days)
or surgery in the previous 4 weeks
1.5 1
Previous DVT/PE 1.5 1
Haemoptysis 1 1
Active cancer 1 1
Outcome
PE unlikely: Score ≤4 Score 0 or 1
PE likely: Score >4 Score ≥2
DVT deep vein thrombosis, PE pulmonary embolism
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The PESI and the sPESI are the two most validated
clinical–physiological risk scoring systems (Table 3). Pa-
tients with a PESI class I–II or sPESI score of 0 are con-
sidered low risk (<3% risk of deterioration) and may be
considered for outpatient management [1]. Aujesky et al.
performed the largest randomised controlled trial of out-
patient PE management to date and demonstrated that
patients with PESI class I or II, who also did not meet
certain exclusion criteria (Table 3), were not put at in-
creased risk by early discharge [2]. If markers of right
ventricular dysfunction or ischaemia (e.g. N-terminal of
the prohormone brain natriuretic peptide or high-
sensitivity troponin) are also negative, the risk of early
PE-related deterioration is <1% [27, 28]. It is unclear
whether these additional biomarkers should be a
mandatory addition to the PESI or sPESI for identifying
patients who can be considered for discharge. Although
these additional tests may improve safety, this may be at
the expense of the number of patients who would qualify
for outpatient management. The HESTIA criteria
provide an alternative approach to risk stratification, in-
corporating several clinical, practical and social issues
(Table 4) [3]. The HESTIA study showed that the
absence of any of these criteria could safely identify pa-
tients for outpatient management of PE [3]. On closer
inspection, the HESTIA criteria are actually very similar
to the exclusion criteria employed in the study by
Aujesky et al. [2] (Table 4). Because the PESI and sPESI
currently have more data supporting their use in risk
stratification across the whole spectrum of patients with
acute PE, the current protocol therefore incorporates
PESI scoring in all patients diagnosed with acute PE
(Fig. 3). The majority of social and practical exclusion
criteria used by Aujesky et al. [2] have been incorpo-
rated. Currently, patients in our centre are also required
to have a normal-sized RV on CTPA to fulfil criteria for
outpatient management. It is possible that the criteria
may become less conservative in the future in light of
recent data and changing guidelines. For example, the
HESTIA investigators observed that the presence of
RV dilatation did not increase risk related to out-
patient management, assuming that no HESTIA cri-
teria were met [3].
Patients without hypotension but with PESI class III–V
or sPESI class >0 are at intermediate risk of early deterior-
ation and require hospital admission. Patients in this
group who have both radiological evidence of right ven-
tricular dysfunction (from CTPA or echocardiography, if
performed) and elevated plasma biomarkers (BNP, NT-
proBNP or troponin) are at intermediate-high risk of de-
terioration; this group require especially close monitoring
and consideration for reperfusion therapy if there is evi-
dence of further deterioration [1]. Other features, such as
Table 3 PESI and sPESI scores [33, 34]
Prediction factors PESI sPESI
Age >80 years Age in years 1
Male gender +10 -
Cancer +30 1
Heart failure +10 1a
Chronic lung disease +10
Pulse ≥110 beats/minute +20 1
Systolic blood pressure <100 mmHg +30 1
Respiratory rate ≥30 breaths/minute +20 -
Temperature <36 °C +20 -





Low risk: Class I: ≤65
Class II: 66–85
PESI = 0
Intermediate risk: Class III: 86–105
High risk: Class IV: 106–125
Class V: >125
PESI =≥1
PESI Pulmonary Embolism Severity Index, sPESI simplified Pulmonary Embolism
Severity Index
aSingle combined category of chronic cardiopulmonary disease
Table 4 Comparison of HESTIA criteria and exclusion criteria
used by Aujesky et al. [2, 3]
HESTIA criteria: Zondag [3] Exclusion criteria: Aujesky [2]
Is the patient haemodynamically
unstable?
SBP <100 mmHg
Is thrombolysis or embolectomy
necessary?
>24 h oxygen to maintain
sats >90%
Oxygen saturation <90%
Active bleeding or high risk
of bleeding
Active bleeding
High risk of bleeding (stroke
within the preceding 10 days,
GI bleed within the last 14 days
or platelet count <75,000/mm3)
PE diagnosed on anticoagulation? Therapeutic anticoagulation
(INR ≥2.0) at diagnosis
Severe pain needing IV pain
medication for >24 h
Chest pain needing opiates




Barriers to treatment adherence
or follow-up
CrCl <30 mL/min Severe renal failure
(CrCl <30 mL/min)
Severe liver impairment
Documented history of HIT HIT
Is the patient pregnant?
Obesity (weight >150 kg)
CrCl creatinine clearance, GI gastrointestinal, HIT heparin-induced
thrombocytopenia, INR international normalised ratio, IV intravenous, PE pul-
monary embolism, SBP systolic blood pressure
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Fig. 3 Patient assessment form
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the presence of DVT on compression ultrasonography
[29] or elevated lactate levels [30], may be useful in further
refining identification of intermediate-to-high risk patients
at particular risk of deterioration.
Step 4: Treatment strategy
Patients at high risk of early deterioration should undergo
reperfusion therapy, most commonly with systemic
thrombolysis, although catheter-directed therapy and sur-
gical embolectomy will sometimes be necessary if there
are significant contraindications to systemic thrombolysis.
Patients at low or intermediate risk of deterioration are
candidates for either LMWH/VKA, or a NOAC. We
would generally treat patients at intermediate-high risk –
in whom subsequent thrombolysis may potentially be ne-
cessary – with LMWH and a VKA. Patients at low risk of
deterioration are considered for outpatient management.
Although currently published studies regarding outpatient
management of acute PE have utilised LMWH and VKA,
the practical benefits of NOACs (especially the NOACs
rivaroxaban and apixaban, which do not require pre-
treatment with LMWH) make them an attractive method
of anticoagulation in patients undergoing outpatient man-
agement. This role of rivaroxaban in outpatient PE man-
agement is currently being investigated in more detail in
the multicentre HoT-PE study [31]. In intermediate-risk
patients who are admitted, reassessment of PESI or sPESI
score after 48 h may identify patients now suitable for
early discharge and outpatient management [1].
Step 5: Follow-up
If patients undergo outpatient management, they are
reviewed within 48 h by the VTE nurse specialist. The
patient’s clinical state is assessed to ensure no clinical
deterioration. Results of initial malignancy screening are
reviewed, including a focused history and examination,
review of blood results and urinalysis. Dependent on the
results of these tests, further tests may be arranged. The
current anticoagulation method is reviewed and a plan
for ongoing anticoagulation is made in conjunction with
the patient. If the patient is treated with rivaroxaban, a
second appointment is made for approximately 21 days
after diagnosis which coincides with the change in
dosing from 15 mg twice daily to 20 mg once daily.
Education and counselling are important components of
patient care. At the time of PE diagnosis, an individual
treatment plan will be provided and treatment options will
be discussed. Later, outpatient appointments help to
ensure patients understand the reasons behind why a PE
occurred, the recommended treatment and why treatment
adherence is important. It is also an opportunity for the
patient to be fully reassured and for any questions or con-
cerns to be discussed.
In Sheffield, we review patients at approximately
3 months following their acute PE at a consultant-led,
combined respiratory-haematology clinic. The patient’s
initial history and radiological investigations are
reviewed to confirm the diagnosis, the nature of the
event (i.e. provoked or unprovoked) and to assess the
likelihood of chronic complications. A proportion of pa-
tients with ongoing, new breathlessness will undergo
further investigation (often a combination of echocardi-
ography, nuclear perfusion scanning and/or computed
tomography pulmonary angiogram) to assess for the
presence of chronic thromboembolic pulmonary hyper-
tension. Plans regarding ongoing anticoagulation manage-
ment are then made. Longer-term anticoagulation is
considered following unprovoked events, whereas anticoa-
gulation can often be stopped after 3 months following
strongly provoked clots. In selected patients thrombophi-
lia testing may be indicated, while D-dimer level testing
after withdrawing anticoagulation may further refine esti-
mates of the risk of recurrence in selected patients with
partially provoked events [32].
Conclusion
The Sheffield VTE management pathways for DVT and PE
are examples of best practice within the UK. These
pathways facilitate the smooth transition of patients from
hospital to home, while maintaining regular patient follow-
up. VTE management for many patients with distal DVT,
proximal DVT or low-risk PE can be safely carried out as
part of ambulatory care, particularly with the involvement of
specialist anticoagulation nurses and the use of NOACs. Use
of a pathway similar to the Sheffield VTE pathway may re-
duce the burden on secondary care and the length of
hospital stays. Patient satisfaction may also increase with
same-day diagnosis, shorter hospital stay, fewer injections,
and follow-up in the same thrombosis service.
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